GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (TSX:AEZS) » Definitions » Cyclically Adjusted Price-to-FCF

AEterna Zentaris (TSX:AEZS) Cyclically Adjusted Price-to-FCF : (As of May. 15, 2024)


View and export this data going back to 1995. Start your Free Trial

What is AEterna Zentaris Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


AEterna Zentaris Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for AEterna Zentaris's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris Cyclically Adjusted Price-to-FCF Chart

AEterna Zentaris Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

AEterna Zentaris Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of AEterna Zentaris's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, AEterna Zentaris's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AEterna Zentaris's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AEterna Zentaris's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where AEterna Zentaris's Cyclically Adjusted Price-to-FCF falls into.



AEterna Zentaris Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

AEterna Zentaris's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, AEterna Zentaris's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-5.951/125.4675*125.4675
=-5.951

Current CPI (Dec. 2023) = 125.4675.

AEterna Zentaris Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -2,128.200 98.604 -2,707.998
201406 -1,156.833 99.473 -1,459.135
201409 -1,205.167 99.394 -1,521.307
201412 -1,425.571 98.367 -1,818.320
201503 -1,835.857 99.789 -2,308.267
201506 -913.091 100.500 -1,139.928
201509 -412.391 100.421 -515.245
201512 -116.273 99.947 -145.962
201603 -118.273 101.054 -146.847
201606 -82.970 102.002 -102.058
201609 -74.870 101.765 -92.309
201612 -93.603 101.449 -115.764
201703 -70.606 102.634 -86.314
201706 -55.574 103.029 -67.678
201709 -43.006 103.345 -52.212
201712 -35.036 103.345 -42.536
201803 131.030 105.004 156.566
201806 -38.232 105.557 -45.443
201809 -19.354 105.636 -22.987
201812 -19.780 105.399 -23.546
201903 -24.506 106.979 -28.741
201906 -16.671 107.690 -19.423
201909 -20.331 107.611 -23.705
201912 -19.450 107.769 -22.644
202003 -15.580 107.927 -18.112
202006 -13.898 108.401 -16.086
202009 -4.221 108.164 -4.896
202012 5.144 108.559 5.945
202103 -2.044 110.298 -2.325
202106 -3.668 111.720 -4.119
202109 -1.559 112.905 -1.732
202112 -2.829 113.774 -3.120
202203 -1.530 117.646 -1.632
202206 -5.160 120.806 -5.359
202209 -4.344 120.648 -4.518
202212 -3.775 120.964 -3.916
202303 -4.580 122.702 -4.683
202306 -4.702 124.203 -4.750
202309 -3.782 125.230 -3.789
202312 -5.951 125.468 -5.951

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AEterna Zentaris  (TSX:AEZS) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


AEterna Zentaris Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


AEterna Zentaris (TSX:AEZS) Business Description

Industry
Traded in Other Exchanges
Address
222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7
AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.